**KEY ASSUMPTIONS**

- **Introduction 12 months after application; 11 applications in September 2009 for introduction in 2nd half of 2010; Pakistan and Nigeria to introduce in 2nd half of 2011; India phased introduction starting in 2014 financed from local government; Rwanda & the Gambia 2009-2010 demand covered with donations.** Source: WHO New & Underused Vaccine Introduction (NUVI) regional calls and other input

- **Available financing for the entire forecast duration for product purchase and introduction expenses; no changes in eligibility criteria; sufficient production capacity to meet demand; all prequalified products meet or exceed TPP and have suitable presentation.** Source: SVS sub team

- **2 years uptake (time to reach peak coverage) except India, Nigeria, Pakistan and Indonesia, with 4 years uptake.** Source: HepB mono introduction analogue

- **PCV3 (3rd dose) coverage projected growing up to 90% from current levels.** Source: SVS sub team based on DTP3 coverage projections in cMYP, if not available, WHO-UNICEF Best Estimate

- **Wastage = 10%, Buffer stocks = 25% of one year full supply; Successful cold chain up scaling at central & local level in all countries where required.** Source: UNICEF SD

- **Population, crude birth rate & infant mortality rates as per medium variant.** Source: 2008 UN population prospect